Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study

被引：0

作者：

Dickinson, Michael ^{[1
,2
]}

Carlo-Stella, Carmelo ^{[3
,4
]}

Morschhauser, Franck ^{[5
,6
]}

Bachy, Emmanuel ^{[7
]}

Corradini, Paolo ^{[8
,9
]}

Iacoboni, Gloria ^{[10
]}

Khan, Cyrus ^{[11
]}

Wrobel, Thomasz ^{[12
]}

Offner, Fritz ^{[13
]}

Trneny, Marek ^{[14
]}

Wu, Shang-Ju ^{[15
]}

Cartron, Guillaume ^{[16
]}

Hertzberg, Mark ^{[17
,18
]}

Sureda, Anna ^{[19
]}

Perez-Callejo, David ^{[20
]}

Lundberg, Linda ^{[20
]}

Relf, James ^{[21
]}

Clark, Emma ^{[21
]}

Humphrey, Kathryn ^{[21
]}

Hutchings, Martin ^{[22
]}

机构：

[1] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Univ Melbourne, Melbourne, Vic, Australia

[3] Humanitas Univ, Milan, Italy

[4] IRCCS Humanitas Res Hosp, Milan, Italy

[5] Hop Claude Huriez, Lille, France

[6] CHU Lille, Lille, France

[7] Ctr Hosp Lyon Sud, Lyon, France

[8] Univ Milan, Milan, Italy

[9] IRCSS Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci, Milan, Italy

[10] Vall dHebron Univ Hosp, Barcelona, Spain

[11] Allegheny Hlth Network, Pittsburgh, PA USA

[12] Uniwersytet Med Wroclawiu, Wroclaw, Poland

[13] Univ Ziekenhuis Gent, Ghent, Belgium

[14] Charles Univ Hosp, Prague, Czech Republic

[15] Natl Taiwan Univ Hosp, Taipei, Taiwan

[16] CHU Montpellier, Montpellier, France

[17] Prince Wales Hosp, Sydney, NSW, Australia

[18] Univ New South Wales, Sydney, NSW, Australia

[19] Inst Catala Oncol Hosp, Barcelona, Spain

[20] F Hoffmann La Roche Ltd, Basel, Switzerland

[21] Roche Prod Ltd, Welwyn Garden City, Herts, England

[22] Rigshosp, Copenhagen, Denmark

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

ABCL; glofitamab; diffuse large B-cell lymphoma; bispecific antibody; relapsed/refractory; phase II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-478

引用

页码：S435 / S435

页数：1

共 50 条

[1] Glofitamab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma and ≥2 Prior Therapies: Results from a Pivotal Phase II Expansion Study
Michael, Dickinson
Carmelo, Carlo-Stella
Franck, Morschhauser
Emmanuel, Bachy
Paolo, Corradini
Gloria, Iacoboni
Cyrus, Khan
Tomasz, Wrobel
Fritz, Offner
Marek, Trneny
Shang-Ju, Wu
Guillaume, Cartron
Mark, Hertzberg
Anna, Sureda
David, Perez-Callejo
Linda, Lundberg
James, Relf
Emma, Clark
Kathryn, Humphrey
Martin, Hutchings
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S39 - S40
[2] Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.
Dickinson, Michael
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Corradini, Paolo
Iacoboni, Gloria
Khan, Cyrus
Wrobel, Tomasz
Offner, Fritz
Trneny, Marek
Wu, Shang-Ju
Cartron, Guillaume
Hertzberg, Mark
Balari, Anna Sureda
Perez-Callejo, David
Lundberg, Linda
Relf, James
Clark, Emma
Humphrey, Kathryn
Hutchings, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Dickinson, Michael J.
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Corradini, Paolo
Iacoboni, Gloria
Khan, Cyrus
Wrobel, Tomasz
Offner, Fritz
Wu, Shang-Ju
Cartron, Guillaume
Hertzberg, Mark
Sureda, Anna
Perez-Callejo, David
Lundberg, Linda
Relf, James
Dixon, Mark
Clark, Emma
Humphrey, Kathryn
Hutchings, Martin
Trney, Marek
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24): : 2220 - 2231
[4] Glofitamab in Patients with relapsed/refractory (R/R) diffuse large B-Cell Lymphoma (DLBCL) and ≥2 prior Lines of Therapy: Key Results of the Phase-II Expansion
Hutchings, M.
Dickinson, M.
Carlo-Stella, C.
Morschhauser, F.
Bachy, E.
Corradini, P.
Iacoboni, G.
Khan, C.
Wrobel, T.
Offner, F.
Trneny, M.
Wu, S. -J.
Cartron, G.
Hertzberg, M.
Sureda, A.
Perez-Callejo, D.
Lundberg, L.
Relf, J.
Clark, E.
Humphrey, K.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 50 - 51
[5] Glofitamab in Relapsed Refractory Diffuse Large B-Cell Lymphoma: Single Center Experience
Yaman, Samet
Candir, Burcu Aslan
Bozan, Ersin
Dal, Mehmet Sinan
Altuntas, Fevzi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S445 - S445
[6] The Use of Glofitamab in Relapsed Diffuse Large B-Cell Lymphoma
Falchi, Lorenzo
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01) : 12 - 15
[7] Glofitamab Monotherapy Demonstrates High Complete Response Rates and Manageable Safety in Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and ≥ 2 Prior Therapies
Song, Yu-Qin
Zhang, Hui-Lai
Huang, Hui-Qiang
Zhang, Qing-Yuan
Jing, Hong-Mei
Wang, Chao
Wu, Chun
Li, Dong-Hang
Dai, Yu
Humphrey, Kathryn
Zhu, Jun
BLOOD, 2022, 140 : 12050 - 12051
[8] Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Harris, Leonard Jeff
Patel, Kruti
Martin, Michael
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 12
[9] Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Kim, Won-Seog
Kim, Tae Min
Cho, Seok-Goo
Jarque, Isidro
Iskierka-Jazdzewska, Elzbieta
Poon, Michelle Limei
Prince, H. Miles
Oh, Sung Yong
Lim, Francesca
Carpio, Cecilia
Tran-Der Tan
Ayyappan, Sabarish
Gutierrez, Antonio
Li, Jingjin
Ufkin, Melanie
Zhu, Min
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth R.
Walewski, Jan
BLOOD, 2022, 140 : 1070 - 1071
[10] Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data
Atesoglu, Elif Birtas
Gulbas, Zafer
Uzay, Ant
Ozcan, Muhit
Ozkalemkas, Fahir
Dal, Mehmet Sinan
Kalyon, Hakan
Akay, Olga Meltem
Deveci, Burak
Bekoz, Huseyin
Sevindik, Omur Gokmen
Toptas, Tayfur
Yilmaz, Fergun
Koyun, Derya
Alkis, Nihan
Alacacioglu, Inci
Sonmez, Mehmet
Yavasoglu, Irfan
Tombak, Anil
Mehtap, Ozgur
Kurnaz, Fatih
Yuce, Orhan Kemal
Karakus, Volkan
Turgut, Mehmet
Kurekci, Derya Deniz
Ayer, Mesut
Keklik, Muzaffer
Buyuktas, Deram
Ozbalak, Murat
Ferhanoglu, Burhan
HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 663 - 673

← 1 2 3 4 5 →